Charles Rudin is the Chief of Thoracic Oncology at Memorial Sloan-Kettering Cancer Center. Dr. Rudin directs a laboratory focused on the development of novel therapeutic approaches to both non-small cell and small cell lung cancers. Dr. Rudin also directs the clinical lung cancer therapeutics program, studying innovative approaches to cancer treatment in patients. Several novel treatment strategies, including re-expression of genes silenced in cancer, targeting of cancer cell death pathways, systemic administration of a cancer-specific virus, and targeting of embryonic developmental signaling pathways are being studied in parallel in the Rudin laboratory and in early phase clinical trials in patients with lung cancer and other solid tumors.